NeoGenomics Advances Personalized Cancer Diagnostics Through RaDaR ST Molecular Residual Disease Test

NeoGenomics showcased its RaDaR ST molecular residual disease test at the European Society for Medical Oncology Congress 2025, highlighting its potential to strengthen drug development for pharmaceutical partners. This development reinforces the company's role in precision oncology and may influence its investment narrative and growth outlook. Despite the recent data presentation, investors should remain cautious about the pressure on clinical revenue growth and the volatility tied to pharma customer unpredictability.